Idexx Laboratories price target lowered to $500 from $525 at Stifel

Stifel lowered the firm’s price target on Idexx Laboratories to $500 from $525 and keeps a Hold rating on the shares after a deep dive to explore a handful of data points relevant to IDEXX’s 2024 pricing power. While its work implies IDEXX likely has more 2024 pricing power than investors realize, Stifel continues to expect a “relatively modest veterinary visit environment,” the analyst tells investors.